It was created a transgenic mouse that expressed exclusively the TCR α-chain of a VSV-specific, H-2Kb-restricted T cell clone (N30.7, Vα2/Vβ13). When the transgenic mice were immunized with the VSV peptide, Vβ13 was again the predominant Vβ element present in VSV-specific CTL populations. However, the TCR Vβ usage was profoundly altered when these transgenic mice were immunized with peptides carrying single replacements near the C terminus of VSV. Peptides with replacements at the N terminus of VSV were able to induce a strong cytotoxic response but did not alter the TCR Vβ usage.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE